コンテンツへスキップ
MediciNova, Inc.
  Message from CEO
  Our Mission
  Company Profile
  Management Team
  History
  Ongoing Clinical Studies
    About MN-166 (Ibudilast)
    ALS
    Oncology / Glioblastoma
    DCM
    CIPN
    ARDS / Lung Injury
    About MN-001(Tipelukast)
    NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  Press Release
  Event
  Media Archive
  Annual Report
  SEC filing
  Stock Quote -TSE
  Stock Quote -Nasdaq
  Historical Price Lookup
  Investment Calculator
  Analyst Coverage
  Corporate Governance
  Information Request
  Corporate Presentation & Resarch Reports
    Progressive Multiple Sclerosis (Progressive MS)
    Amyotrophic Lateral Sclerosis (ALS)
    Oncology / Glioblastoma
    Substance Dependence and Addiction
    MN-166 (ibudilast) News Articles
    MN-166 (ibudilast) Publications
  MN-001 Presentation
  Contact Us
Japanese site
  • About Us
    • Message from CEO
    • Our Mission
    • Company Profile
    • Management Team
    • History
  • Clinical Development
    • Ongoing Clinical Trial
    • MN-166 (Ibudilast)
      • About MN-166 (Ibudilast)
      • ALS
      • Oncology / Glioblastoma
      • DCM
      • CIPN
      • ARDS / Lung Injury
    • MN-001 ( tipelukast)
      • About MN-001(Tipelukast)
      • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  • Presentation
    • MN-166 Presentation
      • Progressive Multiple Sclerosis (Progressive MS)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Oncology / Glioblastoma
      • Substance Dependence and Addiction
      • MN-166 (ibudilast) News Articles
      • MN-166 (ibudilast) Publications
    • MN-001 Presentation
  • Investor Relations
    • News
    • Events
    • Presentations
    • Stock Quote & Chart
    • TSE Stock Quote
    • Analyst Coverage
    • Equity Research
    • SEC Filings
    • Annual Reports
    • Documents & Charters
    • Email Alerts
  • Contact Us

MN-166のオピオイド依存症治療を適応とするフェーズ2a臨床治験に関して第77回アメリカ薬物依存症学会年次総会での発表のお知らせ

MN-166
2015.03.032019.07.22
Page Top
aaa_co
MediciNova, Inc.

関連記事

MN-166

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

MN-001

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020

MN-166

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

MediciNova to Participate in Two Investor Conferences in September

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MN-001

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan

MN-001の進行型NASHを適応とするフェーズ2臨床治験に関してアメリカ肝臓病学会・製薬産業協議会の協賛学会での発表のお知らせ
MN-001(タイペルカスト)の肝線維化を認めるNASH適応に対するFDAのファストトラック指定承認のお知らせ
Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy
    • About Us
      • Message from CEO
      • Our Mission
      • Company Profile
      • Management Team
      • History
    • Clinical Development
      • Ongoing Clinical Trial
      • MN-166 (Ibudilast)
        • About MN-166 (Ibudilast)
        • ALS
        • Oncology / Glioblastoma
        • DCM
        • CIPN
        • ARDS / Lung Injury
      • MN-001 ( tipelukast)
        • About MN-001(Tipelukast)
        • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
    • Presentation
      • MN-166 Presentation
        • Progressive Multiple Sclerosis (Progressive MS)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Oncology / Glioblastoma
        • Substance Dependence and Addiction
        • MN-166 (ibudilast) News Articles
        • MN-166 (ibudilast) Publications
      • MN-001 Presentation
    • Investor Relations
      • News
      • Events
      • Presentations
      • Stock Quote & Chart
      • TSE Stock Quote
      • Analyst Coverage
      • Equity Research
      • SEC Filings
      • Annual Reports
      • Documents & Charters
      • Email Alerts
    • Contact Us
  • MediciNova, Inc.